Ayuda
Ir al contenido

Dialnet


Resumen de Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus

Marta Bonet, David González, José Enrique Baquedano, Elena García, Manuel Altabas, Francesc Casas, Nicolás Feltes, Ferran Ferrer González, Palmira Foro Arnalot, R. Fuentes Raspall, Manuel Galdeano, David Gomez, I. Henríquez, J. Jové Teixidó, Joan Lozano Galán, Javier Maldonado Pijoan, Joel Mases, Ismael Membrive Conejo, Saturio Paredes, Àlvar Roselló, Gemma Sancho, Moisés Mira

  • Background To reach a consensus on recommendations for the management of high-risk and post-operative non-metastatic prostate cancer by a group of Radiation Oncologists in Catalonia dedicated to prostate cancer.

    Methods A modified Delphi approach was employed to reach consensus on controversial topics in Radiation Oncology on high-risk non-metastatic (eight questions) and post-operative (eight questions) prostate cancer. An agreement of at least 75% was considered as consensus. The survey was electronically sent 6 weeks before an expert meeting where topics were reviewed and discussed. A second-round survey for the controversial questions only was sent and answered by participants after the meeting.

    Results After the first round of the survey, 19 experienced Radiation Oncologists attended the meeting and 74% fulfilled the second-round online questionnaire. An agreement of 9 of the 16 questions was accounted for the first round. After the meeting, an additional agreement was reached in 3 questions leading to a final consensus on 12 of the 16 questions. There are still controversial topics like the use of PET for staging of high-risk and post-operative non-metastatic prostate cancer and the optimal dose to the prostate bed in the salvage setting.

    Conclusion This consensus contributes to establish recommendations and a framework to help in prostate cancer radiation therapy and pharmacological management in daily clinical practice of high-risk and post-operative non-metastatic prostate cancer.


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus